# argenx clinical trials: 87 on ClinicalTrials.gov (2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 87 trials with argenx as lead sponsor, 25 of them recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Clinical trials led by argenx: 87 rows for $5, every trial on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. The new rows each week by email, about 2 rows a month: $19 a month. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/company/argenx

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 87
- Recruiting or not yet: 25
- Read on: November 19, 2026

## Trials

The 25 newest of 87, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| September 16, 2026 | NCT07821762 | A Study of Empasiprubart as Add-On Therapy to IVIg in Adult Participants With Guillain-Barré Syndrome | argenx | Phase 2 | Not yet recruiting | Guillain-Barré Syndrome (GBS) | 63 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07821762) |
| August 24, 2026 | NCT07782775 | A Study to Assess the Bioequivalence of Efgartigimod PH20 SC Between Autoinjector and Prefilled Syringe in Healthy Adult Participants | argenx | Phase 1 | Completed | Healthy Volunteer, Healthy Adult Participants | 32 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07782775) |
| August 19, 2026 | NCT07773727 | A Study to Evaluate the Effect of ARGX-121 on the Change in Proteinuria in Adult Participants With IgAN | argenx | Phase 2 | Recruiting | Immunoglobulin A Nephropathy (IgAN) | 120 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07773727) |
| August 12, 2026 | NCT07760818 | A Study to Assess Efficacy and Safety of Efgartigimod in Adults With Sjogren's Disease-associated Sensorimotor Polyneuropathy or Sensory... | argenx | Phase 2 | Not yet recruiting | Sjogrens Disease, Primary Sjögren's Syndrome Painful Sensory Neuropathies | 75 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07760818) |
| August 4, 2026 | NCT07746089 | A Study to Assess Efficacy and Safety of Adimanebart in Adult and Pediatric Participants With DOK7-,MUSK-, AGRN-, or LRP4- Congenital... | argenx | Phase 3 | Not yet recruiting | Congenital Myasthenic Syndrome, CMS | 105 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07746089) |
| June 29, 2026 | NCT07673627 | ADAPT Forward 2 - ISA2 - a Study to Evaluate the Safety, Tolerability and Efficacy of Empasiprubart IV Monotherapy in Participants With... | argenx | Phase 2 | Recruiting | AChR-Ab Seropositive Generalized Myasthenia Gravis, Myasthenia Gravis (MG), MG - Myasthenia Gravis, gMG | 40 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07673627) |
| June 29, 2026 | NCT07673601 | A Study to Assess the Absolute Bioavailability and How Adimanebart SC Moves Through the Body in Healthy Adult Participants | argenx | Phase 1 | Recruiting | Healthy Volunteers (HV), Healthy Volunteer | 52 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07673601) |
| June 10, 2026 | NCT07638566 | A Study to Assess the Correct Dose, Safety and Efficacy of Empasiprubart in Adolescent Participants Aged 12 to Less Than 18 Years With... | argenx | Phase 2/3 | Withdrawn | Chronic Inflammatory Demyelinating Polyradiculoneuropathy, CIDP (Chronic Inflammatory Demyelinating... | 0 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07638566) |
| May 28, 2026 | NCT07612020 | A Study to Assess the Absolute Bioavailability of Empasiprubart SC Administered With an Autoinjector and the Pharmacokinetic Noninferiority... | argenx | Phase 1 | Recruiting | Healthy Volunteers | 130 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07612020) |
| May 28, 2026 | NCT07610564 | A Study to Assess the Effect of Empasiprubart on Nerve Morphology by Ultrasound in Adults With Multifocal Motor Neuropathy | argenx | Phase 1 | Recruiting | Multifocal Motor Neuropathy (MMN) | 60 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07610564) |
| May 19, 2026 | NCT07596849 | A Study to Assess Efficacy and Safety of Efgartigimod PH20 SC PFS in Adult Participants With Graves' Disease. | argenx | Phase 3 | Recruiting | Graves Disease | 230 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07596849) |
| May 19, 2026 | NCT07595653 | A Study to Evaluate the Impact of Efgartigimod on Overall Disease Experience of People Suffering From Generalized Myasthenia Gravis (gMG)... | argenx | Observational | Recruiting | Generalized Myasthenia Gravis (gMG), gMG | 100 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07595653) |
| May 13, 2026 | NCT07583641 | A Study to Learn About How Well the Medicine Efgartigimod Works to Treat Autoimmune Encephalitis In Children 12 Years or Older and Adults | argenx | Phase 2 | Not yet recruiting | Autoimmune Encephalitis (AE) | 170 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07583641) |
| May 6, 2026 | NCT07570316 | A Study to Assess Efficacy and Safety of Efgartigimod PH20 SC PFS in Adult Participants With Graves' Disease | argenx | Phase 3 | Recruiting | Graves' Disease, Graves Disease | 230 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07570316) |
| January 29, 2026 | NCT07377396 | A Study to Assess the Safety of ARGX-124 in Healthy Volunteers | argenx | Phase 1 | Recruiting | Healthy Volunteers | 104 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07377396) |
| December 19, 2025 | NCT07294170 | ADAPT Forward - Master Protocol of a Platform Study to Evaluate the Safety and Efficacy of Multiple Regimens in Participants With... | argenx | Observational | Recruiting | Myasthenia Gravis, MG, gMG, Generalized Myasthenia Gravis, Generalized Myasthenia Gravis (gMG), AChR-Ab Seropositive... | 70 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07294170) |
| December 17, 2025 | NCT07287982 | A Study to Assess the Safety, Tolerability, Efficacy, Pharmacokinetics, and Immunogenicity of Intravenous Administration of ARGX-119 in... | argenx | Phase 2 | Recruiting | Spinal Muscular Atrophy (SMA) | 60 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07287982) |
| December 16, 2025 | NCT07284420 | ADAPT Forward 1 - ISA1 - a Study to Evaluate Empasiprubart IV as add-on Therapy to Efgartigimod IV in Participants With AChR-Ab... | argenx | Phase 2 | Recruiting | AChR-Ab Seropositive Generalized Myasthenia Gravis, Myasthenia Gravis, MG, gMG, Generalized Myasthenia Gravis... | 70 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07284420) |
| December 4, 2025 | NCT07264426 | Real-World Efgartigimod Effectiveness in CIDP: A Prospective Study | argenx | Observational | Recruiting | Chronic Inflammatory Demyelinating Polyradiculoneuropathy, CIDP, CIDP (Chronic Inflammatory Demyelinating... | 200 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07264426) |
| September 26, 2025 | NCT07194850 | A Study of Efgartigimod IV in Participants From 12 Years to Less Than 18 Years of Age With Chronic Immune Thrombocytopenia (ITP) | argenx | Phase 2/3 | Recruiting | Immune Thrombocytopenia (ITP), ITP - Immune Thrombocytopenia, ITP, Immune Thrombocytopenic Purpura, Immune... | 24 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07194850) |
| July 29, 2025 | NCT07091630 | A Study to Assess the Efficacy and Safety of Empasiprubart in Adults With CIDP | argenx | Phase 3 | Recruiting | Chronic Inflammatory Demyelinating Polyneuropathy, CIDP, Chronic Inflammatory Demyelinating Polyradiculoneuropathy | 160 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07091630) |
| May 13, 2025 | NCT06968338 | A Study to Assess the Safety of ARGX-213 in Healthy Volunteers | argenx | Phase 1 | Completed | Healthy Volunteers | 88 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06968338) |
| April 9, 2025 | NCT06920004 | A Study to Assess Efficacy and Safety of Empasiprubart Versus IVIg in Adults With CIDP | argenx | Phase 3 | Recruiting | Chronic Inflammatory Demyelinating Polyneuropathy, CIDP, CIDP - Chronic Inflammatory Demyelinating Polyneuropathy | 218 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06920004) |
| April 3, 2025 | NCT06909214 | A Study to Evaluate the Clinical Outcomes of Efgartigimod PH20 SC in Adults With New-onset Generalized Myasthenia Gravis (gMG) | argenx | Phase 4 | Recruiting | New Onset Generalized Myasthenia Gravis (gMG) | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06909214) |
| January 29, 2025 | NCT06799416 | A Study to Assess the Safety of ARGX-109 in Healthy Volunteers | argenx | Phase 1 | Completed | Healthy Volunteer | 40 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06799416) |

## By phase

| Phase | Trials |
| --- | --- |
| Phase 1 | 19 |
| Phase 2 | 25 |
| Phase 2/3 | 7 |
| Phase 3 | 26 |
| Phase 4 | 2 |
| Not applicable | 1 |
| Observational | 7 |

## By status

| Status | Trials |
| --- | --- |
| Completed | 35 |
| Recruiting | 21 |
| Active not recruiting | 15 |
| Terminated | 7 |
| Not yet recruiting | 4 |
| Enrolling by invitation | 2 |
| Withdrawn | 2 |
| Available | 1 |

## Conditions

| Condition group | Trials |
| --- | --- |
| Myasthenia Gravis | 17 |
| Polyradiculoneuropathy, Chronic Inflammatory Demyelinating | 9 |
| Purpura, Thrombocytopenic, Idiopathic | 8 |
| Pemphigus | 3 |
| Myositis | 3 |
| Dermatomyositis | 3 |
| Myasthenic Syndromes, Congenital | 3 |
| Graves Ophthalmopathy | 2 |
| Polymyositis | 2 |
| Antisynthetase syndrome | 2 |
| Neoplasms | 2 |
| Pemphigoid, Bullous | 2 |
| Kidney Diseases | 2 |
| Urologic Diseases | 2 |
| Glomerulonephritis | 2 |
| Graves Disease | 2 |
| Delayed Graft Function | 1 |
| Amyotrophic Lateral Sclerosis | 1 |
| Postural Orthostatic Tachycardia Syndrome | 1 |
| Post-Acute COVID-19 Syndrome | 1 |
| Glomerulonephritis, IGA | 1 |
| Autoimmune Diseases of the Nervous System | 1 |
| Glomerulonephritis, Membranous | 1 |
| Renal Insufficiency | 1 |
| Scleroderma, Systemic | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Drywall contractors in the United States](https://specstream.ai/data/businesses/drywall-contractors/united-states)
- [Water softening equipment suppliers in the United States](https://specstream.ai/data/businesses/water-softening-equipment-suppliers/united-states)
- [Neuropathology practices in the United States](https://specstream.ai/data/businesses/neuropathology-practices/united-states)
- [Ecuadorian restaurants in the United States](https://specstream.ai/data/businesses/ecuadorian-restaurants/united-states)
- [West African restaurants in the United States](https://specstream.ai/data/businesses/west-african-restaurants/united-states)
- [Occupational therapy clinics in the United States](https://specstream.ai/data/businesses/occupational-therapy-clinics/united-states)
